Nanopath is developing molecular diagnostic platforms to detect viral, bacterial, and fungal pathogens using a single patient sample. The I-Corps alumni company combined nanotechnology, biosensing, data analysis, optics, and molecular biology to create their platform. Founded by Amogha Tadimety, Ph.D. and Alison Burklund, Ph.D., the company has grown to over 15 employees since its founding in 2019. Nanopath has secured over $14M in funding, including SBIR grants and a series A funding round.
